MedTrace Logo

Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients

NCT00316589 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 581

Last updated 2019-01-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to gather information on the safety and immunogenicity of an investigational smallpox vaccine in HIV infected populations. Subjects will receive two vaccinations

Conditions

  • HIV Infections

Interventions

BIOLOGICAL

IMVAMUNE (MVA-BN)

2 immunizations, four weeks apart: 1 x 10E8 TCID50, subcutaneous

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • Bavarian Nordic

    lead INDUSTRY

Principal Investigators

  • Edgar Turner Overton, MD · Washington University School of Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2009-03-31
Completion
2009-10-31

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00316589 on ClinicalTrials.gov